William ‘BJ’ Jones is the Chief Commercial Officer, Migraine & Common Disease of Biohaven Pharmaceuticals, a biopharmaceutical company committed to improving the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders.
BJ has over 25 years of commercial experience in the healthcare industry and has held executive leadership roles of increasing responsibility at Takeda Pharmaceuticals, Astra Zeneca, Bristol-Myers Squibb, Boehringer-Ingelheim and NitroMed.
BJ has significant experience in mass market product launches, including Excedrin Migraine, Abilify®, Farxiga®, Pradaxa®, BiDil® and most recently, Nurtec® ODT (rimegepant).
BJ has successfully built and led diverse commercial teams committed to addressing unmet patient needs across various therapeutic areas, including neuroscience (migraine, schizophrenia, bipolar, depression), cardiovascular (congestive heart failure, atrial fibrillation), diabetes (type 2 – oral and injectable), respiratory, GI, and infectious disease.
BJ holds a Bachelor of Science degree in Human Factors Engineering from the U.S. Air Force Academy, a Master of Science degree in Industrial Engineering from Texas A&M University and an MBA from Stanford Graduate School of Business.